A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Karyopharm Therapeutics Inc
Massive Bio, Inc.
Incyte Corporation
American Regent, Inc.
Astex Pharmaceuticals, Inc.
AbbVie
Newave Pharmaceutical Inc
Asana BioSciences
Prelude Therapeutics
Incyte Corporation
Medigene AG
Tarix Pharmaceuticals
Incyte Corporation
Traws Pharma, Inc.
Novartis
Prescient Therapeutics, Ltd.
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
Millennium Pharmaceuticals, Inc.
The Emmes Company, LLC